A small molecule PTER-selective inhibitor reduces food intake and body weight

Sipei Fu, Lushun Wang, Veronica L Li, Xuchao Lyu, Wei Wei, Xu Shi, Shuliang Deng, Jacob L Barber, Usman A Tahir, Charleen Adams, April Carson, Bertha Hidalgo, Laura M Raffield, James G Wilson, Hlib Razumkov, Shuke Xiao, Jan Spaas, Daniel Fernandez, Tinghu Zhang, Robert E Gerszten, Mark D Benson, Nathanael S Gray, Stephen M Hinshaw, Jonathan Z Long

bioRxiv [Preprint]. 2026 Jan 28:2026.01.26.701829. doi: 10.64898/2026.01.26.701829.

ABSTRACT

PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remain unknown, limiting our ability to harness this pathway therapeutically. Here we solve crystal structures of a eukaryotic PTER in apo and product-bound forms. These structures uncover an unexpected pocket homology between PTER and histone deacetylase (HDAC) enzymes. We exploit this similarity to engineer a first-in-class substrate-competitive PTER inhibitor called PTERi with nanomolar potency and >100-fold selectivity for PTER over HDACs in vitro. Administration of PTERi to diet-induced obese mice reduces feeding, enhances GLP1-RA (glucagon like peptide 1 receptor agonist)-induced weight loss, and prevents weight regain after GLP1-RA discontinuation. The structure of PTER connects histone and metabolite deacetylation into a parallel conceptual framework and enables proof-of-concept data for pharmacological inhibition of PTER in obesity.

PMID:41659642 | PMC:PMC12873775 | DOI:10.64898/2026.01.26.701829